Springer The Cancer Degradome: Proteases and Cancer Biology

Product Description Section 1: The Degradome and its analysis Chapter 1: Protease Genomics and the Cancer Degradome Xose S. Puente, Gonzalo R Ordonez & Carlos López-Otín Chapter 2: The CLIP-CHIP: A focused oligonucleotide microarray platform for transcriptone analysis for the complete human and murine cancer degradomes. Rheinhild Kappelhoff, Claire H.Wilson, & Christopher M. Overall Chapter 3: The Hu/Mu ProtIn chip: A custom dual-species Oligonucleotide Microarray for profiling degradome gene expression in tumours and their microenvironment Donald R.Scwartz, Kamiar Moin, Ekkehard Weber & Bonnie F Sloane Chapter 4: Quantitative Real-Time PCR analysis of degradome gene expression Caroline J Pennington, Robert K. Nuttall, Clara Sampieri -Ramirez, , Matthew Wallard, Simon Pilgrim & Dylan R. Edwards Chapter 5: Identification of protease substrates by mass spectrometry approaches. Mari Enoksson,Wenhong Zhu & Guy Salvesen Chapter 6: Identification of protease substrates by mass spectrometry approaches - 2. Anna Prudova, Ulrich auf dem Keller & Christopher M. Overall Chapter 7: Activity based imaging and biochemical profiling tools for analysis of the cancer degradome. Vincent Dive, Margot Paulick, J.Oliver McIntyre, Lynn M. Matrisan & Matthew Bogyo. Chapter 8: Images of cleavage Kamiar Moin,Mansoureh Sameni, Christopher Jedeszko, Quanwen Li, Mary B. Olive, Raymond R. Mattingly & Bonnie F. Sloane Section 2: Insights into Protease function Chapter 9: Proteolytic pathways: Intersecting cascades in cancer development Nesrine I. Affara & Lisa M, Coussens Chapter 10: Physiological functions of plasminogen activation: Effects of gene deficiences in humans andmice Thomas H. Bugge Chapter 11: The plasminogen activation system in tissue remodelling and cancer invasion Kasper Almholt, Anna Juncker-Jensen, Kirsty Anne Green, Helene Solberg, Leif Roge Lund & John Rømer Chapter 12: The urokinase plasminogen activator receptor as a target for cancer therapy Silvia D'Alessio & Francesco Blasi Chapter 13: The endocytic collagen receptor uPARAP/Endo 180 in cancer invasion and tissue remodelling Thore Hillig, Lars H. Engelholm & Niels Behrendt Chapter 14: Physiological and pathological functions of type II transmembrane serine proteinases:Lessons from transgenic mouse models and human disease-associated mutations. Karin List & Thomas Bugge Chapter 15: Analysis of cysteine cathepsin knockout mice in cancer models Thomas Reinheckel, Vasilena Gocheva, Christoph Peters & Johanna A. Joyce Chapter 16: In vitro and in vivo models of angiogenesis to dissect MMP functions. Sarah Berndt, Françoise Bruyère, Maud Jost & Agnès Noël Chapter 17: The surface transplantation model to study the tumour-host interface Maud Jost, Silvia Vosseler, Silvia Blacher, Norbert E. Fusenig, Margareta Mueller & Agnes Noel Chapter 18: Unravelling the roles of proteases in cell migration in vitro and in vivo Jelena Gavrilovic & Xanthe Scott Chapter 19: New insights into MMP function in adipogenesis Kumari L Andarawewal & Marie-Christine Riol Chapter 20: TIMPs:Extracellular Modifiers in Cancer Development Aditya Murty,William Cruz-Munoz & Rama Khokha Section 3: The interface between Proteolysis and Cell Signalling Chapter 21: Invadopodia: Interface for Invasion Susette C Mueller, Vira V. Artym From the Back Cover Proteases that act in the extracellular environment have been historically associated with tumorigenesis and metastasis by virtue of their ability to carry out "path-clearing" for cancer cells. In the past few years it has become clear that they also shape the pericellular signaling environment, with profound consequences for cell fate and phenotype in both normal development and disease states. The repertoire of proteases that cells and tissues coordinately regulate in order to modulate their local environment is the DEGRADOME – which in humans is represented by at least 569 proteases in five catalytic classes. "The Cancer Degradome: Proteases in Cancer Biol